Table 4.
Association between methylation-based CRP scores and risk of total lung cancer and NSCLC risk, overall and stratified by time to diagnosis, CLUE I/II cohort
| All lung cancersa OR (95% CI) |
Non-small cell lung cancerb OR (95% CI) |
|
|---|---|---|
| CRP Score 1c | 0.76 (0.59, 0.99) | 0.57 (0.40, 0.81) |
| Time to diagnosis ≤ 10 years | 0.84 (0.56, 1.26) | 0.57 (0.33, 0.97) |
| Time to diagnosis > 10 years | 0.67 (0.47, 0.97) | 0.53 (0.32, 0.88) |
| CRP Score 2d | 0.77 (0.61, 0.98) | 0.62 (0.45, 0.84) |
| Time to diagnosis ≤ 10 years | 0.79 (0.54, 1.17) | 0.49 (0.28, 0.85) |
| Time to diagnosis > 10 years | 0.73 (0.53, 1.02) | 0.68 (0.46, 1.00) |
| CRP Score 3e | 0.79 (0.58, 1.07) | 0.65 (0.44, 0.95) |
| Time to diagnosis ≤ 10 years | 0.87 (0.53, 1.42) | 0.64 (0.35, 1.18) |
| Time to diagnosis > 10 years | 0.73 (0.49, 1.09) | 0.62 (0.36, 1.05) |
Bold OR and CI values indicate statistical significance
a208 cases and 208 controls matched for age at blood draw, sex, smoking status, and model further adjusting for BMI, surrogate variables for batch effects, and a methylation-predicted pack-years smoked
b150 cases and 150 controls matched for age at blood draw, sex, smoking status, and model further adjusting for BMI, surrogate variables for batch effects, and a methylation-predicted pack-years smoked. The matched pairs were kept within each stratum
cCpG Score 1 is built using 54 CpG sites and OR results reported per 1 unit of SD of CpG Score 1 (SD 1)
dCpG Score 2 is built using the top 10 highly cell-specific CpG sites and OR results reported per 1 unit of SD of CpG Score 2 (SD 1)
eCpG Score 3 is built using the 10 modestly cell-specific CpG sites and OR results reported per 1 unit of SD of CpG Score 3 (SD 1)